| 2024 | | Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset | 최진혁 |
| 2022 | | Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors | 권민석 |
| 2015 | | Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. | 최진혁 |
| 2007 | | Neutrophilic eccrine hidradenitis in non-small cell lung cancer. | 김유찬 |
| 2020 | | Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) | 안미선 |
| 2019 | | PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data | 고영화, 이수진, 이현우, 정준호, 한재호, 함석진 |
| 2007 | | Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. | - |
| 2007 | | Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5. | 장영주 |
| 2015 | | Prediction of occult lymph node metastasis using volume-based PET parameters in small-sized peripheral non-small cell lung cancer. | 박광주, 박성용, 윤준기, 이수진 |
| 2017 | | Prognostic impact of C-reactive protein/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapy | 고영화, 이현우 |
| 2014 | | Prognostic implication of pulmonary function at the beginning of postoperative radiotherapy in non-small cell lung cancer | 노오규, 오영택 |
| 2017 | | Prognostic significance of lactate dehydrogenase B according to histologic type of non-small-cell lung cancer and its association with serum lactate dehydrogenase | 고영화, 이수진 |
| 2023 | | Prognostic value of pretherapeutic FDG PET/CT in non-small cell lung cancer with pulmonary lymphangitic carcinomatosis | 박용진 |
| 2015 | | Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer. | 박성용 |
| 2016 | | Radiation Therapy-First Strategy After Surgery With or Without Adjuvant Chemotherapy in Stage IIIA-N2 Non-Small Cell Lung Cancer | 노오규, 박래웅, 박성용, 안미선, 오영택, 윤덕용, 이현우, 전미선, 최진혁, 허재성 |
| 2020 | | Residential Radon Exposure and Cigarette Smoking in Association with Lung Cancer: A Matched Case-Control Study in Korea | 신승수, 조남한 |
| 2022 | | Risk factors for pulmonary complications after neoadjuvant chemoradiotherapy followed by surgery for non-small cell lung cancer | 유우식 |
| 2007 | | Serum angiopoietin-2 as a clinical marker for lung cancer. | 박광주, 박주헌, 신승수, 오윤정, 이규성, 황성철 |
| 2006 | | The addition of induction chemotherapy with etoposide, ifosfamide, and cisplatin failed to improve therapeutic outcome of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer -- single institution retrospective analysis. | 강승희, 김효철, 박광주, 박준성, 신승수, 오영택, 오윤정, 이현우, 전미선, 최진혁, 황성철 |
| 2022 | | The efficacy of EGFR-tyrosine kinase inhibitor in non-small cell lung cancer patients with synchronous brain metastasis: a real-world study | 강석윤, 김세혁, 노오규, 노태훈, 신승수, 안미선, 오영택, 이현우, 최용원, 최진혁 |
| 2012 | | The features of radiation induced lung fibrosis related with dosimetric parameters | 김미화, 노오규, 박경주, 박광주, 박혜진, 오영택, 전미선 |
| 2023 | | Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial | 최진혁 |
| 2001 | | Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. | 강승희, 김현수, 김효철, 남동기, 박광주, 오영택, 이이형, 임호영, 전미선, 최진혁, 황성철 |
